ArticleTherapeutic advances in hematology2017

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.

Sikander Ailawadhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.